New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
09:07 EDTPCYCPharmacyclics has several positive catalysts, says RBC Capital
RBC Capital believes that Pharmacyclics provided conservative guidance, while the company is poised to report higher than expected 2014 revenue and expert feedback on its Imbruvica drug is positive. The firm cut its price target on the shares to $110 from $150 but keeps an Outperform rating on the stock.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
09:10 EDTPCYCPharmacyclics initiates cancer study of ibrutinib with AstraZeneca's MEDI4736
Pharmacyclics (PCYC) initiated PCYC-1135-CA, a multi-center study that will investigate the use of ibrutinib in combination with MEDI4736, an investigational, anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca (AZN). The Phase Ib/II study will examine the safety, tolerability and effectiveness of this investigational combination in individuals with relapsed or refractory non-small cell lung cancer, breast cancer, and pancreatic cancer. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech.
March 30, 2015
07:24 EDTPCYCStifel to hold a bus tour
BioTrek: 2015 West Coast Healthcare Therapeutics Bus Tour travels throughout San Francisco on March 30-April 1.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use